the aid library

LIST OPTIONS

Filter

2842

Download (373)

View PDF (665)

Framework of Indicators and Targets for laboratory strengthening under the end tb strategy

World Health Organization (2016) C_WHO

Download (236)

View PDF (362)

Assist - The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)

R. Humeniuk, S. Henry-Edwards, R. Ali; et al. World Health Organization WHO (2010) C_WHO

Manual for use in primary care. There is substantial evidence for the benefits of screening and brief intervention in primary health care for alcohol problems. However, there is a need for screening and brief interventions with cross-cultural relevance for substances other than alcohol or tobacco,... more

External Link

Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study

L. R. Augustemak de Lima; E. L. Petroski; Y. M. F. Moreno; et al. PLOS ONE (2018) CC

Research Article PLOS ONE | https://doi.org/10.1371/journal.pone.0190785 January 10, 2018

Download (299)

View PDF (347)

Características epidemiológicas de tuberculosis pulmonar en establecimiento penitenciario de varones de Trujillo – Perú

Hidalgo, R.; L.A. Chimoy and C. Tunoque (2017) C1

Acta Med Peru. 2017;34(3):182-7; El objetivo del presente trabajo es conocer la magnitud del problema de la TB y sus principales características epidemiológicas en la población del penal de varones de penal de varones de Trujillo, que sirva de base para plantear las mejores soluciones terapéutic... more

Download (198)

View PDF (233)

Western Pacific regional framework to end TB: 2021-2030

World Health Organization WHO (2022) C_WHO

his Framework begins with a desired future scenario and considers actions and interventions necessary to get there. It advocates for holistic view to address tuberculosis. The Framework revisits challenges and actions in four layers: TB specific; challenges in health systems that influence TB care; ... more

Download (230)

View PDF (316)

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment
recommended

World Health Organization WHO (2022) C_WHO

The Quadripartite Organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Organisation for Animal Health (WOAH, founded as OIE), and the World Health Organization (WHO) – collaborate to drive the change and tra... more

Download (215)

View PDF (230)

Special edition: HIV in MSM

I. Steffens; K. Hagmaier; K. Wilson; et al. Eurosurveillance (Europe’s journal on infectious disease epidemiology, prevention and control); European Centre for Disease Prevention and Control (2015) C2

Eurosurveillance Impact Factor 5.7 June 2015 www.eurosurveillance.org Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe

Download (217)

View PDF (225)

Practice Guidelines for Treating Gambling-Related Problems

Korn, D.A. and H.J. Shaffer (2004) CC

An Evidence-Based Treatment Guide for Clinicians

Download (279)

View PDF (324)

Guidance on mainstreaming biodiversity for nutrition and health

World Health Organization WHO (2020) C_WHO

This report aims to support countries in the necessary transition toward healthier, more sustainable diets by integrating biodiversity in food-based interventions to support nutrition and health. It is intended to help guide decision-makers in the health, nutrition and other sectors, to: Consider... more

Download (158)

View PDF (196)

The Georgian national HIV/AIDS strategic plan for 2016–2018

CCM Georgia (2019) C2

Endorsed by the CCM Georgia on April 15th 2015 Accessed: 26.09.2019

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (18276)

View PDF (2776)

Paediatrics for Doctors in Papua New Guinea

Frank Shann and John Vince (2003)

A guide for doctors providing health services for children. 2nd edition

Download (239)

View PDF (404)

Improving Prison Conditions by Strengthening the Monitoring of HIV, HCV, TB and Harm Reduction (Portugal)

N. H. Ponters, A. P. Dores CIES IUL; ISCTE IUL; European Union (2015) C2

Mapping Report - Portugal

Download (5688)

View PDF (1597)

Pharmaceutical management and prescribing pattern of antimalarial drugs in the public health facilities in Dar-es-Salaam, Tanzania

Richard Sebastian Silumbe (2011) C1

Master of Science in Pharmaceutical Management Dissertation

Download (388)

View PDF (592)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (253)

View PDF (400)

The global doctor

Willott C et al. UCL Institute for Global Health and Development Education Research Centre, Institute of Education (2012) C2

This report explores the reasons why global health is critical to medicine and what this means for medical education. It argues that an understanding of global health is important for all students and practicing doctors, rather than being an ‘add-on’ or ‘option’ for specialization.

Download (497)

View PDF (1985)

International Health Emergency Response Plan- Marburg Virus Disease

World Health Organization WHO (2017) C_WHO

On 17 October 2017, the Ugandan Ministry of Health notified WHO of a confirmed Marburg outbreak of Marburg Virus disease (MVD) in Kween district, Eastern Uganda. The outbreak was officially declared by the Ministry of health on 19 October 2017. As of 7 November, four cases of MVD have been reported... more

Download (370)

View PDF (1022)

Kenya National Clinical Nutrition and Detection Reference Manual

Kenya Ministry of Health (2010) CC

Download (1234)

View PDF (1434)

World Health Organization Surgical Safety Checklist

Woodman, N.; and I. Walker World Health Organization WHO (2016) C_WHO

Patient Safety tutorial 325

External Link

Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses

N. Schoenfeld, W. Haas, E. Richter, et al. (2016) C2

Empfehlungen zur Diagnostik und Therapie nichttuberkulöser Mykobakteriosen des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose (DZK) und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP). Schönfeld N et al. Recommendations of the German Central Committee… Pneumolo... more

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment recommended

One health joint plan of action (‎2022‒2026)‎: working together for the health of humans, animals, plants and the environment
recommended